BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Need for Advanced 3D Imaging During Breast Cancer Awareness Month

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based technologies for more accurate breast cancer screening, diagnosis, and treatment, marked Breast Cancer Awareness Month by emphasizing the limitations of current imaging tools and the significant opportunity for its flagship IzoView Breast CT Imaging System. With more than 2.3 million new breast cancer cases reported globally each year—and over 315,000 expected in the U.S. in 2025—Izotropic underscored the urgent need for true high-resolution 3D imaging, especially for women with dense breast tissue, which affects roughly 50% of women and diminishes the accuracy of compression-based screening. As the global breast imaging market grows from $5.4 billion in 2024 to a projected $8.69 billion by 2030, IzoView aims to address the unmet demand for superior diagnostic precision, reducing missed cancers, false positives, and costly follow-up procedures that currently total an estimated $8 billion annually in the U.S.

To view the full press release, visit https://ibn.fm/rdrQc

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN